Listen
IXPRIM and ZALDIAR (tramadol/paracetamol) - Moderate to severe pain
Opinions on drugs -
Posted on
Dec 12 2024
Reason for request
First listing
Summary of opinion
Favourable opinion for reimbursement in the symptomatic treatment of moderate to severe pain.
The use of IXPRIM and ZALDIAR should be restricted to patients whose moderate to severe pain is considered to require a combination of tramadol and paracetamol.
No clinical added value of the new forms in non-pre-cut blister strips compared to the forms already available in individual pre-cut blister strips.
Clinical Benefit
| Substantial |
The clinical benefit of IXPRIM 37.5 mg/325 mg film-coated tablets and ZALDIAR 37.5 mg/325 mg film-coated tablets (tramadol/paracetamol) is substantial in the MA indication. |
Clinical Added Value
| no clinical added value |
These medicinal products are range supplements that do not provide any clinical added value (CAV V) compared to the forms already listed. |
English version
Contact Us
Évaluation des médicaments
